...
首页> 外文期刊>Annals of Thoracic Medicine >Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease
【24h】

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease

机译:沙特肺病诊断和治疗指南:左心疾病引起的肺动脉高压

获取原文
           

摘要

Pulmonary hypertension (PH) due to left heart disease is the most common cause of pulmonary hypertension in the western world. It is classified as WHO PH group II. Different pathophysiologic abnormalities may take place in this condition, including pulmonary venous congestion and vascular remodeling. Despite the high prevalence of WHO group 2 PH, the major focus of research on PH over the past decade has been on WHO group 1 pulmonary arterial hypertension (PAH). Few investigators have focused on WHO group 2 PH; consequently, the pathophysiology of this condition remains poorly understood, and no specific therapy is available. Clinical and translational studies in this area are much needed and have the potential to positively affect large numbers of patients. In this review, we provide a detailed discussion upon the pathophysiology of the disease, the recent updates in classification, and the diagnostic and therapeutic algorithms.
机译:左心疾病引起的肺动脉高压(PH)是西方世界引起肺动脉高压的最常见原因。它被归类为WHO PH组II。在这种情况下可能发生不同的病理生理异常,包括肺静脉充血和血管重塑。尽管WHO 2组PH的患病率很高,但在过去十年中,PH的研究重点一直放在WHO 1组肺动脉高压(PAH)上。很少有研究者关注世卫组织第二组PH。因此,对该病的病理生理学知之甚少,并且没有具体的治疗方法。这方面的临床和转化研究非常必要,并且有可能对大量患者产生积极影响。在这篇综述中,我们对疾病的病理生理学,分类的最新更新以及诊断和治疗算法进行了详细讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号